These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1554914)

  • 1. Choosing a treatment modality for ESRD. The Canadian perspective.
    Prichard S
    ASAIO J; 1992; 38(1):1-2. PubMed ID: 1554914
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of alternative treatments in end-stage renal disease.
    Karlberg I
    Transplant Proc; 1992 Feb; 24(1):335. PubMed ID: 1539301
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost analysis of dialysis treatments for end-stage renal disease (ESRD).
    Goeree R; Manalich J; Grootendorst P; Beecroft ML; Churchill DN
    Clin Invest Med; 1995 Dec; 18(6):455-64. PubMed ID: 8714789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal dialysis is the best cost-effective alternative for maintaining dialysis treatment.
    Arrieta J; Rodríguez-Carmona A; Remón C; Pérez-Fontán M; Ortega F; Sánchez Tomero JA; Selgas R
    Nefrologia; 2011; 31(5):505-13. PubMed ID: 21959716
    [No Abstract]   [Full Text] [Related]  

  • 6. Economics of dialysis and renal transplantation in the developing world.
    Chugh KS; Jha V; Chugh S
    Transplant Proc; 1999 Dec; 31(8):3275-7. PubMed ID: 10616473
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost analysis of renal replacement therapies in Finland.
    Salonen T; Reina T; Oksa H; Sintonen H; Pasternack A
    Am J Kidney Dis; 2003 Dec; 42(6):1228-38. PubMed ID: 14655195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the treatment of end-stage renal disease in Brazil.
    Sesso R; Eisenberg JM; Stabile C; Draibe S; Ajzen H; Ramos O
    Int J Technol Assess Health Care; 1990; 6(1):107-14. PubMed ID: 2113888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of costs of health insurance, substitution therapy in chronic renal insufficiency].
    Chanut C; Barnouin F; Benech JM; Bouvier P; Briat C; Hecht M; Pollini J; Soutif C; Toselli A
    Rev Epidemiol Sante Publique; 1991; 39(4):353-64. PubMed ID: 1754701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness analysis of alternative treatments of end-stage renal disease: Philippine experience.
    Naidas OD; Chan-Licuanan KR; Velasco VP; Dalay CV; Bayog DV; Rosete-Liquete RM
    Transplant Proc; 1998 Nov; 30(7):3116. PubMed ID: 9838375
    [No Abstract]   [Full Text] [Related]  

  • 11. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
    Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
    Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the evidence that peritoneal dialysis is underutilized as an ESRD therapy?
    Gokal R; Blake PG; Passlick-Deetjen J; Schaub TP; Prichard S; Burkart JM
    Semin Dial; 2002; 15(3):149-61. PubMed ID: 12100453
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs and added value of haemodialysis and peritoneal dialysis outsourcing agreements.
    Lamas Barreiro JM; Alonso Suárez M; Saavedra Alonso JA; Gándara Martínez A
    Nefrologia; 2011; 31(6):656-63. PubMed ID: 22130280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost of dialysis in France].
    Zambrowski JJ
    Nephrol Ther; 2016 Apr; 12 Suppl 1():S95-7. PubMed ID: 26972098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic cost of dialysis: a comparison between peritoneal dialysis and in-center hemodialysis in a Spanish unit.
    Rodríguez-Carmona A; Perez Fontán M; Bouza P; García Falcón T; Valdés F
    Adv Perit Dial; 1996; 12():93-6. PubMed ID: 8865880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of dialysis in Canada.
    Prichard SS
    Nephrol Dial Transplant; 1997; 12 Suppl 1():22-4. PubMed ID: 9075224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-medical factors that impact on ESRD modality selection.
    Nissenson AR; Prichard SS; Cheng IK; Gokal R; Kubota M; Maiorca R; Riella MC; Rottembourg J; Stewart JH
    Kidney Int Suppl; 1993 Feb; 40():S120-7. PubMed ID: 8445833
    [No Abstract]   [Full Text] [Related]  

  • 18. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF; Dratwa M; Wiedemann ME
    Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia.
    Hooi LS; Lim TO; Goh A; Wong HS; Tan CC; Ahmad G; Morad Z
    Nephrology (Carlton); 2005 Feb; 10(1):25-32. PubMed ID: 15705178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dilemmas of patient treatment for end-stage renal disease.
    Schmidt RW; Blumenkrantz M; Wiegmann TB
    Am J Kidney Dis; 1983 Jul; 3(1):37-47. PubMed ID: 6346866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.